H.C. Wainwright Thinks Insmed’s Stock is Going to Recover

By Jason Carr

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Insmed (NASDAQ: INSM) today. The company’s shares opened today at $10.62, close to its 52-week low of $9.02.

According to TipRanks.com, Fein is a 1-star analyst with an average return of -3.1% and a 35.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, DBV Technologies S.A. – American, and Proteostasis Therapeutics Inc.

Insmed has an analyst consensus of Strong Buy.

The company has a one year high of $19.30 and a one year low of $9.02. Currently, Insmed has an average volume of 262.4K.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. Most recently, in September 2015, Donald Hayden, a Director at INSM sold 25,000 shares for a total of $601,278.

Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. The company is focused on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. Insmed was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.